Show simple item record

dc.contributor.authorSiller, Anita
dc.contributor.authorWachter, Gregor A
dc.contributor.authorNeururer, Sabrina
dc.contributor.authorPfeifer, Bernhard
dc.contributor.authorAstl, Manfred
dc.contributor.authorBorena, Wegene
dc.contributor.authorKimpel, Janine
dc.contributor.authorElmer, Sebastian
dc.contributor.authorSpöck, Franziska
dc.contributor.authorVales, Anja
dc.contributor.authorMühlbacher, Annelies
dc.contributor.authorGaber, Manfred
dc.contributor.authorWilleit, Peter
dc.contributor.authorSchennach, Harald
dc.date.accessioned2022-01-06T11:52:24Z
dc.date.available2022-01-06T11:52:24Z
dc.date.issued2021-12
dc.identifier.issn0043-5325
dc.identifier.otherPMC8546400
dc.identifier.other34698961
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/332181
dc.description.abstractBACKGROUND: Seroepidemiological studies provide important insight into the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV‑2) in our society. We aimed to determine seropositivity of SARS-CoV‑2 antibodies and its cross-sectional correlates in a large cohort of blood donors. METHODS: In this observational cohort study, we tested healthy blood donors residing in Tyrol, Austria, for SARS-CoV‑2 antibodies using the Abbott SARS-CoV‑2 IgG chemiluminescent microparticle immunoassay. We estimated 95% confidence intervals (95% CI) of seroprevalences using bootstrapping and tested for differences by participant characteristics using logistic regression. FINDINGS: Between 8 June and 4 September 2020, we screened 5345 healthy individuals at local blood donor sessions (mean age 42.7 years, SD 13.5 years, 46.7% female). Overall seroprevalence was 3.1% (95% CI 2.7-3.6%, 165 cases), which is 5.1-fold higher (95% CI 4.5-6.0%) than the case number identified by the health authorities in the state-wide testing program (0.6%; 4536 out of 757,634). Seroprevalence was higher in the district Landeck (16.6%, P < 0.001) and in individuals aged < 25 years (4.7%, P = 0.043), but did not differ by gender, blood types, or medication intake. The odds ratio for seropositivity was 2.51 for participants who had travelled to Ischgl (1.49-4.21, P = 0.001), 1.39 who had travelled to other federal states (1.00-1.93, P = 0.052), and 2.41 who had travelled abroad (1.61-3.63, P < 0.001). Compared to participants who had a suspected/confirmed SARS-CoV‑2 infection but were seronegative, seropositive participants more frequently reported loss of smell (odds ratio = 2.49, 1.32-4.68, P = 0.005) and taste (odds ratio = 2.76, 1.54-4.92, P = 0.001). CONCLUSION: In summer 2020, SARS-CoV‑2 seroprevalence in Tyrolean blood donors was 3.1%. Our study revealed regional variation and associations with young age, travel history and specific symptoms.
dc.languageeng
dc.publisherSpringer Science and Business Media LLC
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceessn: 1613-7671
dc.sourcenlmid: 21620870R
dc.subjectCross-sectional studies
dc.subjectepidemiology
dc.subjectSeroprevalence
dc.subjectSeropositivity
dc.subjectCovid-19
dc.titlePrevalence of SARS-CoV-2 antibodies in healthy blood donors from the state of Tyrol, Austria, in summer 2020.
dc.typeArticle
dc.date.updated2022-01-06T11:52:23Z
prism.publicationNameWien Klin Wochenschr
dc.identifier.doi10.17863/CAM.79627
dcterms.dateAccepted2021-09-28
rioxxterms.versionofrecord10.1007/s00508-021-01963-3
rioxxterms.versionVoR
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0/
dc.contributor.orcidWilleit, Peter [0000-0002-1866-7159]
dc.identifier.eissn1613-7671
cam.issuedOnline2021-10-26


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International